|
Generex is dedicated to the research, development and commercialization of drugs delivery via the buccal mucosa. Generex seeks to out-license its RapidMist™ product programs and identify in-licensing opportunities and acquisitions in the areas of diabetes, drug delivery, cancer, H5 avian influenza, HIV, generic and branded prescription drugs, 505(b)2 product candidates, and late stage development opportunities.
|
|
Antigen Express
Antigen Express (www.antigenexpress.com), is a platform and product-based company developing proprietary vaccine formulations for large, unmet medical needs. Our focus is on stimulating critical members of the immune response, known as T helper cells.
Fertin Pharma
Fertin Pharma (www.fertin.com), is a world leader in the development and manufacture of medical chewing gum and is working in partnerships with a wide range of well-respected pharmaceutical companies. Fertin Pharma's patent protected MediChew® technology is based on unique know-how with controlled release of active substances from gum bases, fully documented release testing procedures, taste modification, and development of gum bases.
Cardinal Health
Ranked No. 19 on the Fortune 500, Cardinal Health (www.cardinal.com), manufactures or packages products for nine out of the top 10 pharmaceutical companies and most leading biotechnology companies. The company manufactures or packages more than half a billion doses of pharmaceuticals every day.
Leosons General Trading Company
Leosons (www.leosons.com), a leading distributor of North American healthcare products in the region and the Company's Marketing and Distribution partner in the Middle East, recently entered into a collaboration with Sheikh Saeed Bin Obaid Al Maktoum, a member of the Royal Family of United Arab Emirates. Recently, the two parties have established Medpro LLC with offices to be set up in the Dubai Healthcare City. Medpro is expected to market the Company's products.
Adcock Ingram
Adcock Ingram (www.adcock.co.za), part of the Tiger Brands Group, is a leading South African pharmaceutical company with an 11.4% share of the private healthcare market. Adcock Ingram has an extensive range of prescription, generic, and over-the-counter products and also provides life saving hospital equipment and diagnostic products and services.
PharmaBrand SA
Ecuador-based Pharmabrand (www.pharmabrand.com), a distributor of pharmaceutical products, was established in June, 2000 with the acquisition of an Ecuadorian pharmaceuticals plant from Schering-Plough Corporation. Its management team, led by Dr. Cid, has extensive experience in the pharmaceutical industry. Dr. Cid holds a Doctoral Degree in Pharmacy and Chemistry from the University of Chile and a Master of Business Administration degree from Columbia University in New York. He has also undertaken graduate studies in strategic management at Harvard Business School. Dr. Cid has more than 30 years' experience in the multinational pharmaceuticals industry, having held executive positions with Schering Plough, Pfizer and Merck. He served as General Manager & Regional Director of Latin America for Pfizer.
Shreya Life Sciences Pvt
Shreya Life Sciences Pvt. Ltd. (www.shreya.co.in), a leading Indian-based pharmaceutical company. Shreya is the fourth largest distributor of insulin in the Indian insulin product market with a compound annual growth rate of 38% (per C MARC market research). Shreya has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments including cardiology, neuropathy, and diabetes. The company has business operations in India, Russia, the Commonwealth of Independent States, and African countries. The parties are making arrangements for the expansion of extant production facilities to meet the anticipated demand for the product in India and other jurisdictions where governmental approvals are pending.
For business development opportunities, please contact:
Business Development
Phone: 416-364-2551
Fax: 416-364-9363
E-mail: info@generex.com
The technology allows for antigen-specific stimulation or suppression of a T-helper response to virtually any antigen of known pathogenic potential. Consequential, Antigen Express is building a deep pipeline of therapeutics aimed at a variety of major diseases, including cancer, infectious diseases and autoimmune-based syndromes.
Antigen Express therapies are based on highly selective modulation of the immune response, in contrast to most current immunomodulation strategies that are in general non-specific. This lack of specificity is the prime source for unwanted side effects. The therapies developed at Antigen Express intervene at the critical stage of antigen presentation to modulate the immune response. This targeted approach results in a potent up or down regulation of critical members of the immune system.
The technologies developed at Antigen Express are novel and highly complementary to existing approaches of immune modification. Therefore, the company is uniquely positioned to develop partnerships where Antigen Express technology enhances or augments the corporate partners’ technology or product portfolios.
|
